If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.
Skylar Jeremias
Advertisement
Articles by Skylar Jeremias
Advertisement
Latest Updated Articles
FDA Grants Priority Review for DapagliflozinJanuary 8th 2021
Advertisement
Advertisement
Trending on HCPLive
1
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
4
5 Hepatology Headlines You Missed in May 2026
5